Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1002 in Advanced Solid Tumors
NCT05719558Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Mar 2023
- Primary completion
- Apr 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP1002 in solid tumor, colorectal cancer (CRC), prostate cancer (PCa) and 1 more (18 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities up to 24 months, Number of participants with Adverse Events up to 25 months and 6 more. Started Mar 2023; status: recruiting.
02
Drugs
ASP1002
03
Conditions
solid tumorcolorectal cancer (CRC)prostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05719558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719558.